Eyenovia (EYEN)
(Delayed Data from NSDQ)
$1.07 USD
-0.10 (-8.55%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.08 +0.01 (0.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EYEN 1.07 -0.10(-8.55%)
Will EYEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EYEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYEN
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
EYEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates
Other News for EYEN
Eyenovia & SGN Nanopharma collaborate to develop treatment for chronic dry eye disease
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
Eyenovia, SGN Nanopharma announce collaboration agreement
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
Eyenovia, Senju sign collaboration agreement